Physician profile
Marna Seitz
NPI 1508295304
$8,524.61
in general payments reported to CMS, 2019-2025
39 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,061 · 2022: $1,394 · 2023: $1,573 · 2024: $1,854 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,069.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,195.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,121.61 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $782.99 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $666.02 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.77 | 2021-2025 | Jardiance, Synjardy |
| Abbvie INC. | $522.98 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $408.91 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.61 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $257.07 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $236.03 | 2022-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $221.47 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $213.16 | 2021-2023 | Hetlioz |
| Astellas Pharma US INC | $208.99 | 2022-2025 | Veozah, Myrbetriq |
| Nestle Healthcare Nutrition INC. | $186.43 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $181.84 | 2021-2023 | Seglentis, Livalo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $153.58 | 2021-2025 | |
| Glaxosmithkline, LLC. | $150.12 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $121.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $112.67 | 2021-2022 | |
| Abbott Laboratories | $109.05 | 2021-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $101.99 | 2021-2022 | |
| Corium, LLC | $93.72 | 2022-2023 | Adlarity |
| Eisai INC. | $72.08 | 2021-2022 | |
| Amarin Pharma, INC. | $67.01 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.14 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.16 | 2023-2025 | Caplyta |
| Medtronic, INC. | $46.30 | 2024 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $42.78 | 2021-2022 | |
| Philips North America LLC | $40.95 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $33.84 | 2024-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $29.63 | 2022 | |
| Esperion Therapeutics, INC. | $27.19 | 2023-2024 | Nexletol |
| Daiichi Sankyo INC. | $26.05 | 2021 | |
| Biogen, INC. | $16.70 | 2021 | |
| Radius Health, INC. | $16.39 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.39 | 2024 | Voquezna |
| Medicure Pharma INC. | $14.78 | 2021 | |
| Currax Pharmaceuticals LLC | $13.85 | 2025 | Contrave |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marna Seitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.